Cargando…

Efficacy and safety of Zhibitai in combination with atorvastatin for lipid lowering in patients with coronary heart disease

BACKGROUND: Zhibitai, a natural lipid-lowering Chinese medicine, is well tolerated in patients and has low incidence of adverse events. In this study, we evaluated the efficacy, safety, and side effects of Zhibitai in combination with low dose Atorvastatin compared to high dose Atorvastatin in patie...

Descripción completa

Detalles Bibliográficos
Autores principales:	Xu, Danyan, Hu, Jiahui, Wu, Qinghua, Du, Zhiming, Xue, Yusheng, Zhang, Xu, Li, Yi, Chen, Yushan, Chen, Xiaoping, Zhang, Hong, Zhao, Shuiping
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2017
Materias:	Clinical Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5823641/ https://www.ncbi.nlm.nih.gov/pubmed/29507705 http://dx.doi.org/10.18632/oncotarget.18329

Ejemplares similares

Zhibitai and low-dose atorvastatin reduce blood lipids and inflammation in patients with coronary artery disease
por: Zhao, Yuhong, et al.
Publicado: (2017)

Efficacy and safety of Zhibitai in treating coronary heart disease patients with hyperlipemia: A protocol for systematic review and meta-analysis
por: Chen, Mingtai, et al.
Publicado: (2020)

Efficacy and safety of zhibitai in the treatment of hyperlipidemia: A systematic review and meta-analysis
por: Wang, Chunyang, et al.
Publicado: (2022)

Atorvastatin improves coronary flow and endothelial function in patients with coronary slow flow
por: Niu, Hongmei, et al.
Publicado: (2018)

Association between the TIMD4-HAVCR1 variants and serum lipid levels, coronary heart disease and ischemic stroke risk and atorvastatin lipid-lowering efficacy
por: Zhang, Qing-Hui, et al.
Publicado: (2018)

Effect of CETP Polymorphism on Atorvastatin Lipid-Regulating Effect and Clinical Prognosis of Patients with Coronary Heart Disease
por: Gu, Guo-Long, et al.
Publicado: (2014)

Cholesteryl Ester Transfer Protein Gene and Effectiveness of Lipid Lowering of Atorvastatin
por: Kolovou, Genovefa, et al.
Publicado: (2010)

ANGPTL4 variants and their haplotypes are associated with serum lipid levels, the risk of coronary artery disease and ischemic stroke and atorvastatin cholesterol-lowering responses
por: Yang, Qian, et al.
Publicado: (2018)

Association of genetic variations with pharmacokinetics and lipid-lowering response to atorvastatin in healthy Korean subjects
por: Woo, Hye In, et al.
Publicado: (2017)

Immediate effect of intensive atorvastatin therapy on lipid parameters in patients with acute coronary syndrome
por: Vondrakova, Dagmar, et al.
Publicado: (2010)

Therapeutic effects of atorvastatin and ezetimibe compared with double-dose atorvastatin in very elderly patients with acute coronary syndrome
por: Liu, Zhi, et al.
Publicado: (2017)

Comparison of Low-Dose Rosuvastatin with Atorvastatin in Lipid-Lowering Efficacy and Safety in a High-Risk Pakistani Cohort: An Open-Label Randomized Trial
por: Arshad, Abdul Rehman
Publicado: (2014)

Evaluation of efficacy and safety of combined rosuvastatin and atorvastatin in treating with coronary heart disease: A protocol for systematic review and meta-analysis
por: Li, Ke, et al.
Publicado: (2021)

Comparing the combination therapy of ezetimibe and atorvastatin with atorvastatin monotherapy for regulating blood lipids: a systematic review and meta-analyse
por: Ai, Cong, et al.
Publicado: (2018)

Vitamin D Levels and Lipid Response to Atorvastatin
por: Pérez-Castrillón, José Luis, et al.
Publicado: (2010)

Atorvastatin reduces lipopolysaccharide-induced expression of cyclooxygenase-2 in human pulmonary epithelial cells
por: Wu, ShangJie, et al.
Publicado: (2005)

Use of Atorvastatin in Lipid Disorders and Cardiovascular Disease in Chinese Patients
por: Ye, Yi-Cong, et al.
Publicado: (2015)

Comparison of rosuvastatin and atorvastatin for lipid lowering in patients with type 2 diabetes mellitus: results from the URANUS study
por: Berne, Christian, et al.
Publicado: (2005)

Effects of aerobic exercise on lipids and lipoproteins
por: Wang, Yating, et al.
Publicado: (2017)

Cardioprotective Effects of Atorvastatin plus Trimetazidine in Percutaneous Coronary Intervention
por: Lin, Xuefeng, et al.
Publicado: (2013)

Efficacy and safety of hybutimibe in combination with atorvastatin for treatment of hypercholesteremia among patients with atherosclerotic cardiovascular disease risk equivalent: A multicenter, randomized, double-blinded phase III study
por: Qi, Litong, et al.
Publicado: (2022)

Imaging of Intracellular and Extracellular ROS Levels in Atherosclerotic Mouse Aortas Ex Vivo: Effects of Lipid Lowering by Diet or Atorvastatin
por: Ekstrand, Matias, et al.
Publicado: (2015)

MicroRNA-20a-5p Downregulation by Atorvastatin: A Potential Mechanism Involved in Lipid-Lowering Therapy
por: Saavedra, Kathleen, et al.
Publicado: (2022)

Sex-Specific Influence of the SCARB1 Rs5888 SNP on the Serum Lipid Response to Atorvastatin in Patients with Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention
por: Wu, Dong-Feng, et al.
Publicado: (2020)

Atorvastatin lowers (68)Ga-DOTATATE uptake in coronary arteries, bone marrow and spleen in individuals with type 2 diabetes
por: Oostveen, Reindert F., et al.
Publicado: (2023)

Risk factors and coronary artery outcomes of coronary artery aneurysms differing in size and emergence time in children with Kawasaki disease
por: Liu, Jie, et al.
Publicado: (2022)

Intensified lipid-lowering treatment with alirocumab in patients with coronary heart disease
por: Steffens, Daniel, et al.
Publicado: (2021)

Impact of the Gut Microbiota on Atorvastatin Mediated Effects on Blood Lipids
por: Zimmermann, Friederike, et al.
Publicado: (2020)

Therapeutic effect of irbesartan combined with atorvastatin calcium in the treatment of rats with coronary heart disease
por: Li, Tao, et al.
Publicado: (2018)

Atorvastatin and sildenafil lower blood pressure and improve endothelial dysfunction, but only atorvastatin increases vascular stores of nitric oxide in hypertension()
por: Guimarães, Danielle A., et al.
Publicado: (2013)

Safety of atorvastatin in Asian patients within clinical trials
por: Chan, Juliana C. N., et al.
Publicado: (2016)

Emerging evidences for the opposite role of apolipoprotein C3 and apolipoprotein A5 in lipid metabolism and coronary artery disease
por: Dai, Wen, et al.
Publicado: (2019)

Atorvastatin and prevention of contrast induced nephropathy following coronary angiography
por: Bidram, Peyman, et al.
Publicado: (2015)

Effect of Atorvastatin on Serial Changes in Coronary Physiology and Plaque Parameters
por: Lee, Cheol Hyun, et al.
Publicado: (2022)

ITPKC polymorphism (rs7251246 T > C), coronary artery aneurysms, and thrombosis in patients with Kawasaki disease in a Southern Han Chinese population
por: Liu, Jie, et al.
Publicado: (2023)

Effect of atorvastatin therapy on borderline vulnerable lesions in patients with acute coronary syndrome
por: Yu, Dan-Qing, et al.
Publicado: (2011)

Risk Factors for Resistance to Intravenous Immunoglobulin Treatment and Coronary Artery Abnormalities in a Chinese Pediatric Population With Kawasaki Disease: A Retrospective Cohort Study
por: Liu, Jie, et al.
Publicado: (2022)

Changes in Homocysteine Levels Affect Serum Lipid Response to Atorvastatin in Patients With Acute Coronary Syndrome: A Retrospective Observational Study
por: Wu, Dong-Feng, et al.
Publicado: (2020)

A novel direct method to determine adherence to atorvastatin therapy in patients with coronary heart disease
por: Kristiansen, Oscar, et al.
Publicado: (2019)

Tongxinluo Capsule Combined with Atorvastatin for Coronary Heart Disease: A Systematic Review and Meta-Analysis
por: Liu, Qiao, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_chhvpq3b5da5guuh91mq7ip837